Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome

Overview

Patients with myelodysplastic syndrome (MDS) have an ineffective hemopoiesis and often suffer from anemia. This can lead to red blood cell transfusion dependency and iron overload. Iron overload can affect the liver and lead to liver fibrosis and worst case cirrhosis. Ferritin is usually used to monitor the iron overload. In this study MDS patients will have a transient elastography performed which measures the liver's stiffness. The purpose is to investigate whether liver stiffness measurements are coherent to ferritin levels.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: June 2015

Detailed Description

Transient elastography is noninvasive and has no side effects. No liver biopsy will be performed due to serious side-effects and risks in this patientgroup. The results of the transient elastography will be compared to the patient's ferritin levels and the numbers of months the patients have had MDS to find out if there is a correlation. Furthermore we will compare the liver stiffness measurements in the patients with higher ferritin levels to those who have lower ferritin levels. We will also compare the liver stiffness measurements in patients who are red blood cell transfusion dependent compared to those who are red blood cell transfusion independent. We will also compare liver stiffness measurements in the patients with a high alanine aminotransferase (ALAT) compared to those with normal ALAT.

Interventions

  • Other: Transient elastography
    • All patients will have a transient elastography performed as a measure of liver stiffness.

Arms, Groups and Cohorts

  • Patients with myelodysplastic syndrome
    • Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable

Clinical Trial Outcome Measures

Primary Measures

  • Liver stiffness
    • Time Frame: Transient elastography (Fibroscan) 5 minutes
    • Liver stiffness is measured in kilopascal (kPa)
  • Iron overload: Ferritin
    • Time Frame: Blood samples 5 minutes
    • Ferritin is measured in micrograms per liter

Secondary Measures

  • Disease period
    • Time Frame: Information regarding time of diagnosis will be obtained retrospectively
    • Period of disease will be calculated in months
  • Red blood cell transfusion dependency
    • Time Frame: Information regarding transfusion will be obtained retrospectively
    • Transfusion dependency will be defined as having at least one red blood cell transfusion every other eight weeks over a period of four months prior to the date of the fibroscan. Red blood cell dependency will be either “yes” or “no”
  • Liver inflammation: Alanine aminotransferase
    • Time Frame: Blood samples 5 minutes
    • Alanine aminotransferase is measured in units per liter

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with a bone marrow describing myelodysplasia Among these: – Patients with myelodysplastic syndrome (MDS) – Patients with acute myeloid leukemia (AML) transformed from MDS – Patients with chronic myelomonocytic leukemia (CMML) with dysplasia – Patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable Exclusion Criteria:

Body mass index (BMI) of 30 or higher than 30

  • History with other known liver diseases Among these: – Patients with chronic viral hepatitis C infection – Patients with chronic viral hepatitis B infection – Patients with alcoholic liver cirrhosis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zealand University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Klas Raaschou-Jensen, Principal Investigator, Consultant at department of hematology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.